| Literature DB >> 33457229 |
Yunze Dong1, Wei Zhai2, Yunfei Xu1.
Abstract
BACKGROUND: Numerous epidemiological studies have confirmed that diabetes can promote the development of malignant tumors. However, the relationship between renal cell carcinoma (RCC) and diabetic nephropathy (DN) is still controversial. This study aimed to investigate the genes that are co-expressed in DN and RCC in order to gain a better understanding of the relationship between these diseases, and to identify potential biomarkers and targets for the treatment of DN-related RCC.Entities:
Keywords: Gene analysis; biomarkers; diabetic nephropathy (DN); renal cell carcinoma (RCC)
Year: 2020 PMID: 33457229 PMCID: PMC7807343 DOI: 10.21037/tau-19-911
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Figure 1GO analysis and KEGG pathway enrichment. (A) DN-related GO analysis for DEGs; (B) KEGG pathway of DN-related DEGs; (C) RCC-related GO analysis for DEGs; (D) KEGG pathway of RCC-related DEGs, and dot colors represent negative Log10(P values). GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DN, diabetic nephropathy; DEGs, differentially expressed genes; RCC, renal cell carcinoma.
Figure 2Hierarchical clustering analysis of DN-related differentially expressed genes. (A) results of hierarchical clustering analysis for DEGs expression in relation to cellular response to acid chemical; (B) results of hierarchical clustering analysis for DEGs expression in relation to extracellular matrix organization; (C) results of hierarchical clustering analysis for DEGs expression in relation to extracellular structure organization; (D) results of hierarchical clustering analysis for DEGs expression in relation to platelet degranulation. Red, greater expression. Blue, less expression. DN, diabetic nephropathy; DEGs, differentially expressed genes.
Figure 3Hierarchical clustering analysis of RCC-related differentially expressed genes (DEGs). (A) Results of hierarchical clustering analysis for the expression of DEGs in relation to the organization of extracellular structure; (B) results of hierarchical clustering analysis for the expression of DEGs in relation to leukocyte migration; (C) results of hierarchical clustering analysis for the expression of DEGs in relation to neutrophil activation; (D) results of hierarchical clustering analysis for the expression of DEGs in relation to response to oxygen levels. Red, high expression; Blue, low expression. RCC, renal cell carcinoma.
Figure 4Protein-protein interaction (PPI) network analysis. (A) PPI network of DN-related DEGs; (B) PPI network of RCC-related DEGs. Red, greater degree; yellow, lesser degree; (C) Venn diagrams of DEGs. PPI network and Venn diagrams: (I) PPI networks of DEGs from A and B constructed using the String database (threshold >0.4); (II) Venn diagrams of DEGs related to DN and RCC, respectively. DN, diabetic nephropathy; DEGs, differentially expressed genes; RCC, renal cell carcinoma.
24 DEGs related to DN and RCC
| Genes | Gene name | P value |
|---|---|---|
|
| Albumin | 3.82757E−06 |
|
| Glucose-6-phosphatase catalytic subunit | 0.00022495 |
|
| Epidermal growth factor | 0.000414252 |
|
| Phosphoenolpyruvate carboxykinase 1 | 7.27637E−05 |
|
| Alcohol dehydrogenase 1B (class I), beta polypeptide | 0.004123934 |
|
| Clusterin | 0.002382186 |
|
| ADP ribosylation factor like GTPase 4C | 0.000208268 |
|
| Collagen type XV alpha 1 chain | 1.32548E−06 |
|
| V-set and immunoglobulin domain containing 4 | 0.000470776 |
|
| Actinin alpha 1 | 0.000178285 |
|
| Membrane spanning 4-domains A4A | 0.000178285 |
|
| Ribonuclease A family member k6 | 0.000251524 |
|
| SPARC like 1 | 9.03479E−05 |
|
| Olfactomedin like 2B | 0.020197939 |
|
| Thrombospondin 2 | 0.000178285 |
|
| Apolipoprotein C1 | 0.000178285 |
|
| Collagen type I alpha 2 chain | 0.008832521 |
|
| Collagen type VI alpha 3 chain | 0.000178285 |
|
| Collagen type III alpha 1 chain | 0.000178285 |
|
| Polo like kinase 2 | 0.001742339 |
|
| Fibronectin 1 | 0.002382186 |
|
| Versican | 0.000208268 |
|
| Keratin 19 | 0.003055744 |
|
| Transforming growth factor beta induced | 0.006804421 |
DN, diabetic nephropathy; RCC, renal cell carcinoma; DEGs, differentially expressed genes.
Figure 5Relationship of urogenital disease and cancer related to co-expressed genes based on the Comparative Toxicogenomics Database (CTD). (A) The interactions of ALB in urogenital disease and cancer; (B) the interaction of COL1A2 in urogenital disease and cancer; (C) the interaction of COL3A1 in urogenital disease and cancer; (D) the interaction of FN1 in urogenital disease and cancer; (E) the interaction of G6PC in urogenital disease and cancer; (F) the interaction of PCK1 in urogenital disease and cancer.
Figure 6Validation of the gene expression levels of hub genes between normal kidney and RCC tissues in the GEPIA database. (A) COL1A2 was significantly upregulated in RCC compared with normal tissues; (B) COL3A1 was significantly upregulated in RCC compared with normal tissues; (C) FN1 was significantly upregulated in RCC compared with normal tissues; (D) ALB was significantly downregulated in RCC compared with normal tissues; (E) G6PC was significantly downregulated in RCC compared with normal tissues; (F) PCK1 was significantly downregulated in RCC compared with normal tissues (P<0.01). The red * represents P<0.01. GEPIA, the Gene Expression Profiling Interactive Analysis; RCC, renal cell carcinoma; KIRC, kidney renal clear cell carcinoma.
Figure 7Overall survival and disease-free survival analysis of key genes in RCC (based on TCGA data in GEPIA). (A) The expression levels of G6PC were significantly associated with the overall survival of patients with RCC; (B) the expression levels of PCK1 were significantly associated with overall survival in patients with RCC; (C) the expression levels of G6PC were significantly associated with disease-free survival in patients with RCC; (D) the expression levels of PCK1 were associated with disease-free survival in patients with RCC (P<0.05).
The gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment among predicted miRNAs and co-DEGs
| Genes | Predicted miRNAs | Category | Function | P value |
|---|---|---|---|---|
|
| hsa-miR-496 | KEGG pathway | Steroid hormone biosynthesis | 5.27E−08 |
| hsa-miR-141-3p | Hippo signaling pathway | 2.02E−05 | ||
| Endocrine and other factor-regulated calcium reabsorption | 2.47E−05 | |||
| GO terms | Macromolecular complex assembly | 0.00030452 | ||
| Epidermal growth factor receptor signaling pathway | 0.000423173 | |||
| Post-translational protein modification | 0.000428322 | |||
| G2/M transition of mitotic cell cycle | 0.000515818 | |||
| Keratan sulfate biosynthetic process | 0.00053589 | |||
| Fc-epsilon receptor signaling pathway | 0.000720702 | |||
| Keratan sulfate metabolic process | 0.001811958 | |||
| Sulfur compound metabolic process | 0.001941431 | |||
| Phospholipid metabolic process | 0.005110673 | |||
| ECM-receptor interaction | 1.46E−48 | |||
| Mucin type O-glycan biosynthesis | 8.96E−09 | |||
| KEGG pathway | PI3K-Akt signaling pathway | 0.006961302 | ||
| TNF signaling pathway | 0.009107875 | |||
| Signaling pathways regulating pluripotency of stem cells | 0.009974988 | |||
|
| hsa-miR-29c-3p | GO terms | Fc-epsilon receptor signaling pathway | 3.59E−17 |
| hsa-let-7b-5p | neurotrophin TRK receptor signaling pathway | 2.73E−15 | ||
| hsa-let-7c-5p | Extracellular matrix disassembly | 1.20E−12 | ||
| hsa-let-7f-5p | Post-translational protein modification | 3.56E−12 | ||
| hsa-miR-29a-3p | Extracellular matrix organization | 3.92E−09 | ||
| Nucleobase-containing compound catabolic process | 8.99E−09 | |||
| Platelet activation | 1.77E−08 | |||
|
| hsa-miR-29c-3p | KEGG pathway | ECM-receptor interaction | 8.17E−49 |
| hsa-miR-29a-3p | Mucin type O-glycan biosynthesis | 7.54E−09 | ||
| hsa-miR-29b-3p | Focal adhesion | 0.001207023 | ||
| hsa-miR-98-5p | PI3K-Akt signaling pathway | 0.006207862 | ||
| hsa-let-7b-5p | GO terms | Fc-epsilon receptor signaling pathway | 4.44E−17 | |
| Neurotrophin TRK receptor signaling pathway | 3.49E−15 | |||
| Extracellular matrix disassembly | 1.42E−12 | |||
| Post-translational protein modification | 4.28E−12 | |||
| Cellular protein metabolic process | 1.98E−11 | |||
|
| hsa-miR-200c-3p | KEGG pathway | Thyroid hormone signaling pathway | 0.024934027 |
| hsa-miR-200b-3p | Cysteine and methionine metabolism | 0.028989042 | ||
| hsa-miR-429 | Sphingolipid metabolism | 0.047606983 | ||
| hsa-miR-199a-3p | ErbB signaling pathway | 0.048121598 | ||
| hsa-miR-144-3p | GO terms | Toll-like receptor TLR1:TLR2 signaling pathway | 0.010695034 | |
| Toll-like receptor TLR6:TLR2 signaling pathway | 0.010695034 | |||
| Toll-like receptor 10 signaling pathway | 0.017791067 | |||
|
| hsa-miR-200c-3p | KEGG pathway | ECM-receptor interaction | 1.62E−70 |
| hsa-miR-429 | Focal adhesion | 3.49E−05 | ||
| hsa-miR-200b-3p | PI3K-Akt signaling pathway | 0.000700807 | ||
| hsa-miR-3163 | Signaling pathways regulating pluripotency of stem cells | 0.001671859 | ||
| hsa-miR-29a-3p | GO terms | Cell death | 0.000888739 | |
| Fibroblast growth factor receptor signaling pathway | 0.001026574 | |||
| Cellular lipid metabolic process | 0.0010844 | |||
| MyD88-independent toll-like receptor signaling pathway | 0.001319258 | |||
|
| hsa-miR-1297 | KEGG pathway | Hippo signaling pathway | 0.000298106 |
| hsa-miR-548m | Thyroid hormone signaling pathway | 0.024032656 | ||
| hsa-miR-330-3p | Sphingolipid metabolism | 0.037579593 | ||
| hsa-miR-101-3p | Adherens junction | 0.037579593 | ||
| hsa-miR-3163 | GO terms | Cellular component disassembly involved in execution phase of apoptosis | 3.19E−05 | |
| Cell proliferation | 0.000266671 | |||
| Cellular protein metabolic process | 0.000394966 | |||
| Macromolecular complex assembly | 0.00042068 | |||
| Fc-epsilon receptor signaling pathway | 0.000562009 | |||
| Response to stress | 0.000562009 |
Figure 8Co-expression analysis for the miRNA-target interactions. (A) There is a significant negative correlation between hsa-miR-429 and FN1 with RCC; (B) there is a significant negative correlation between hsa-miR-200b-3p and FN1 with RCC; (C) there is a significant negative correlation between hsa-miR-29a-3p and G6PC with RCC; (D) there is a significant negative correlation between hsa-miR-200c-3p and G6PC with RCC; (E) there is a significant negative correlation between hsa-miR-29c-3p and COL1A2 with RCC; (F) there is a significant negative correlation between hsa-miR-29c-3p and COL3A1 with RCC (P<0.05).
Figure 9Genetic alterations associated with 3 key genes. (A) A visual summary of genetic alterations (data from RCC in TCGA, provisional) shows the genetic alteration of 3 key genes which were altered in 21 (6%) of 354 RCC patients; (B) the total alteration frequency of 3 key genes is illustrated; (C) the network contains 51 nodes, including 3 key genes and the 50 most frequently altered neighbor genes. Relationship of 3 key genes is also illustrated.
Figure 10A flow chart for analysis. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DN, diabetic nephropathy; RCC, renal cell carcinoma; CDEGs, co-expressed diferentially expressed genes; CTD, the Comparative Toxicogenomics Database; GEPIA, the Gene Expression Profiling Interactive Analysis.